These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26582803)

  • 1. Development of an HTRF Assay for the Detection and Characterization of Inhibitors of Catechol-O-Methyltransferase.
    Kimos M; Burton M; Urbain D; Caudron D; Martini M; Famelart M; Gillard M; Barrow J; Wood M
    J Biomol Screen; 2016 Jun; 21(5):490-5. PubMed ID: 26582803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
    Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
    J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue and interspecies comparison of catechol-
    Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
    Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues important for rational COMT inhibition.
    Dingemanse J
    Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical issues with COMT inhibitors in Parkinson's disease.
    Waters C
    Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
    Robinson RG; Smith SM; Wolkenberg SE; Kandebo M; Yao L; Gibson CR; Harrison ST; Polsky-Fisher S; Barrow JC; Manley PJ; Mulhearn JJ; Nanda KK; Schubert JW; Trotter BW; Zhao Z; Sanders JM; Smith RF; McLoughlin D; Sharma S; Hall DL; Walker TL; Kershner JL; Bhandari N; Hutson PH; Sachs NA
    ACS Chem Neurosci; 2012 Feb; 3(2):129-40. PubMed ID: 22860182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
    Nutt JG
    Lancet; 1998 Apr; 351(9111):1221-2. PubMed ID: 9643737
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
    Kiss LE; Soares-da-Silva P
    J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA; Soares-da-Silva P
    Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders.
    Jatana N; Apoorva N; Malik S; Sharma A; Latha N
    Cent Nerv Syst Agents Med Chem; 2013; 13(3):166-94. PubMed ID: 24450388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
    Schapira AH; Obeso JA; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M; Ukai W; Ozawa H; Riederer P
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
    Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
    J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMT inhibitors: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S45-51. PubMed ID: 12211139
    [No Abstract]   [Full Text] [Related]  

  • 20. [Tolcapone in the management of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(6):71-8. PubMed ID: 18688929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.